Page 1 | Search Results | Blood | American Society of Hematology

1-11 of 11

Sort by

Sort Order Select

Journal Articles

Expanded Proliferation Centers (PCs) Identify a Histological Subtype of Chronic Lymphocytic Leukemia (“Accelerated” CLL) with Adverse Clinical Outcome.

Eva Gine, Antonio Martinez, Neus Villamor, Armando Lopez-Guillermo, Mireia Camós, Daniel Martinez, Jordi Esteve, Xavier Calvo, Ana Muntañola, Pau Abrisqueta, Emili Montserrat, Elias Campo, Francesc Bosch

Blood (2009) 114 (22): 2335.

https://doi.org/10.1182/blood.V114.22.2335.2335

Published: 2009

Journal Articles

Biological Analysis and Prognostic Significance of Proliferative Cellular Compartment in Chronic Lymphocytic Leukemia (CLL).

Pau Abrisqueta, Neus Villamor, Ana Muntañola, Carles Codony, Mireia Camós, Eva Calpe, Maria Joao Baptista, Gonzalo Gutiérrez-García, Xavier Calvo, Rita Coutinho, Gabriela Ghita, Carol Moreno, Cristina Lopez, Olga Salamero, Emili Montserrat, Francesc Bosch

Blood (2009) 114 (22): 667.

https://doi.org/10.1182/blood.V114.22.667.667

Published: 2009

Journal Articles

Chronic Lymphocytic Leukemia Apoptotic Cell Death Induced by Glucocorticoids Is Mediated by BIM and GILZ and Can Be Predicted by FKBP5 Basal Expression Levels.

Maria Joao Baptista, MSc, Ana Muntañola, MD, Carles Codony, PhD, Eva Calpe, Eva Fernandez, Marta Crespo, PhD, Pau Abrisqueta, MD, Eva Gine, MD, Susana G Kalko, PhD, Pedro Jares, PhD, Emili Montserrat, MD, PhD, Francesc Bosch, MD, PhD

Blood (2009) 114 (22): 1236.

https://doi.org/10.1182/blood.V114.22.1236.1236

Published: 2009

Journal Articles

Rituximab, Fludarabine, Cyclophosphamide, and Mitoxantrone (R-FCM) Is a Highly Active Chemoimmunotherapy Regimen for Chronic Lymphocytic Leukemia.

Francesc Bosch, MD, PhD, Pau Abrisqueta, MD, Neus Villamor, MD, PhD, Maria Jose Terol, MD, Josep-Maria Ribera, MD, Eva Gonzalez-Barca, MD, Marcos Gonzalez, MD, Eugenia Abella, MD, Julio Delgado, MD, Yolanda Gonzalez, MD, Secundino Ferrer, MD, Felix Carbonell, MD, Lourdes Escoda, MD, Isidro Jarque, MD, Encarnacion Monzo, MD, Ana Muntañola, MD, Olga Salamero, MD, Emili Montserrat, MD

Blood (2008) 112 (11): 2097.

https://doi.org/10.1182/blood.V112.11.2097.2097

Published: 2008

Journal Articles

Chronic Lymphocytic Leukemia (CLL): A Comparative Analysis of Protein Expression Profiles in Peripheral Blood Cells at Diagnosis and upon Disease Progression.

Eva Gine, MD, Ana Muntañola, MD, Marta Crespo, PhD, Eva Calpe, Maria Joao Gomes, Emili Montserrat, MD, Francesc Bosch, MD

Blood (2007) 110 (11): 1129.

https://doi.org/10.1182/blood.V110.11.1129.1129

Published: 2007

Journal Articles

Histone H1.2 Releasing under Different Apoptotic Stimuli in Chronic Lymphocytic Leukemia (CLL).

Eva Gine, MD, Marta Crespo, PhD, Ana Muntañola, MD, Eva Calpe, Maria Joao Gomes, Neus Villamor, MD, Emili Montserrat, MD, Francesc Bosch, MD

Blood (2007) 110 (11): 1141.

https://doi.org/10.1182/blood.V110.11.1141.1141

Published: 2007

Journal Articles

Preliminary Results of the Combination Rituximab, Fludarabine, Cyclophosphamide and Mitoxantrone (R-FCM) Followed by Rituximab Maintenance in Previously Untreated Chronic Lymphocytic Leukemia (CLL).

Francesc Bosch, MD, PhD, Ana Muntañola, MD, Neus Villamor, MD, Maria Jose Terol, MD, Elena Gonzalez-Barca, MD, Josep Maria Ribera, MD, PhD, Marcos Gonzalez, MD, Eugenia Abella, MD, Julio Delgado, MD, Felix Carbonell, MD, PhD, Jose A. Garcia-Marco, MD, PhD, Lourdes Escoda, MD, Secundino Ferrer, MD, E. Monzo, MD, Yolanda Gonzalez, MD, Pau Abrisqueta, MD, Olga Salamero, MD, Eva Gine, MD, Emili Montserrat, MD, PhD

Blood (2007) 110 (11): 626.

https://doi.org/10.1182/blood.V110.11.626.626

Published: 2007

Journal Articles

Computed Tomography (CT) Predicts Response Duration in Patients with Chronic Lymphocytic Leukemia (CLL) in Complete Response (CR) by Conventional, NCI-Working Group, Criteria.

Francesc Bosch, MD, Ana Muntañola, MD, Ana Ferrer, MD, Marcos González, MD, Eva Gine, MD, Eugenia Abella, MD, Santi Gardella, MD, Javier Briones, MD, Eva González-Barca, MD, Lourdes Escoda, MD, Elena Pérez-Ceballos, MD, Antoni Asensi, MD, Maria José Sayas, MD, Joan Besalduch, MD, Emili Montserrat, MD

Blood (2006) 108 (11): 2835.

https://doi.org/10.1182/blood.V108.11.2835.2835

Published: 2006

Journal Articles

FMNL-1 (Formin-Like 1) Gene in Chronic Lymphocytic Leukemia (CLL) Is Overexpressed in Young Patients with Adverse Prognostic Factors and Poor Outcome.

Eva Calpe, PhD, Patricia M.B. Favaro, PhD, Marta Crespo, PhD, Maria Joao Baptista, PhD, Ana Muntañola, MD, Eva Giné, MD, Sara Saad, MD, Emili Montserrat, MD, PhD, Francesc Bosch, MD

Blood (2006) 108 (11): 2775.

https://doi.org/10.1182/blood.V108.11.2775.2775

Published: 2006

Journal Articles

Clinical significance of minimal residual disease, as assessed by different techniques, after stem cell transplantation for chronic lymphocytic leukemia

Carol Moreno, Neus Villamor, Dolors Colomer, Jordi Esteve, Eva Giné, Ana Muntañola, Elias Campo, Francesc Bosch, Emili Montserrat

Blood (2006) 107 (11): 4563–4569.

https://doi.org/10.1182/blood-2005-09-3634

Published: 2006

Journal Articles

Clinical Characteristics and Outcome of a Large Series of Patients with Chronic Lymphocytic Leukemia (CLL) According to ZAP-70 Expression.

Francesc Bosch, MD, Marta Crespo, PhD, Neus Villamor, MD, Ana Muntañola, MD, Ana Ferrer, MD, Abel Domingo, MD, Maria Rozman, MD, Ciril Rozman, MD, Armando Lopez-Guillermo, MD, Emili Montserrat, MD

Blood (2004) 104 (11): 14.

https://doi.org/10.1182/blood.V104.11.14.14

Published: 2004

NARROW

Expanded Proliferation Centers (PCs) Identify a Histological Subtype of Chronic Lymphocytic Leukemia (“Accelerated” CLL) with Adverse Clinical Outcome.

Biological Analysis and Prognostic Significance of Proliferative Cellular Compartment in Chronic Lymphocytic Leukemia (CLL).

Chronic Lymphocytic Leukemia Apoptotic Cell Death Induced by Glucocorticoids Is Mediated by BIM and GILZ and Can Be Predicted by FKBP5 Basal Expression Levels.

Rituximab, Fludarabine, Cyclophosphamide, and Mitoxantrone (R-FCM) Is a Highly Active Chemoimmunotherapy Regimen for Chronic Lymphocytic Leukemia.

Chronic Lymphocytic Leukemia (CLL): A Comparative Analysis of Protein Expression Profiles in Peripheral Blood Cells at Diagnosis and upon Disease Progression.

Histone H1.2 Releasing under Different Apoptotic Stimuli in Chronic Lymphocytic Leukemia (CLL).

Preliminary Results of the Combination Rituximab, Fludarabine, Cyclophosphamide and Mitoxantrone (R-FCM) Followed by Rituximab Maintenance in Previously Untreated Chronic Lymphocytic Leukemia (CLL).

Computed Tomography (CT) Predicts Response Duration in Patients with Chronic Lymphocytic Leukemia (CLL) in Complete Response (CR) by Conventional, NCI-Working Group, Criteria.

FMNL-1 (Formin-Like 1) Gene in Chronic Lymphocytic Leukemia (CLL) Is Overexpressed in Young Patients with Adverse Prognostic Factors and Poor Outcome.

Clinical significance of minimal residual disease, as assessed by different techniques, after stem cell transplantation for chronic lymphocytic leukemia

Clinical Characteristics and Outcome of a Large Series of Patients with Chronic Lymphocytic Leukemia (CLL) According to ZAP-70 Expression.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only